Tag: TB Drugs

TB Alliance and Mylan to Advance Tuberculosis Drug

Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V., today announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigationa...

Schrödinger and TB Alliance joined forces to develop new TB drugs

Schrödinger and TB Alliance announced a research collaboration to speed the development of next-generation tuberculosis treatments by leveraging computational platform for drug discovery.

EECA states join their efforts in fight against communicable diseases

Minsk is hosting the Eastern Europe and Central Asia (EECA) Regional Consultation on Expanding Access to Affordable and Quality Assured Antiretroviral and Antituberculosis Medicines.

Belarus is hosting the second EECA consultation on ARV and TB drugs

Belarus' Deputy Premier, spoke at the Eastern Europe and Central Asia Regional Consultation on Expanding Access to Affordable and Quality Assured ARV and TB Medicines in Minsk.

Russian TB vaccine has successfully completed preclinical studies

Minister of Health of the Russian Federation Veronika Skvortsova made an announcement on the Margins of UN General Assembly.

GSK’s experimental TB vaccine shows promising results in clinical trials

GSK and Aeras reported that GSK’s M72/AS01E candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection.

Canadian researchers revealed more effective TB treatment

Treatment of latent tuberculosis is set to transform after a pair of studies from the McGill University Health Centre revealed that a shorter treatment was safer and more effective.

Kazakhstan added new TB drugs to its list of free medicines

A number of new innovative drugs were added to the list of free medicines including those for the treatment of tuberculosis. This was announced by the Kazakhstan’s Minister of Health Elzhan Birtanov at a public meeting.

GENERIUM may start exporting Diaskintest to Iran in the near future

In the near future, GENERIUM plans to start exporting Diaskintest to the Islamic Republic of Iran for its use as one of the main methods for diagnosis of latent and active forms of tuberculosis.

Eisai will develop a new treatment for tuberculosis aided by US scientists

Japanese pharmaceutical company Eisai entered into a joint research agreement with the Broad Institute, Mycobacteria Research Laboratories at Colorado State University and the University of Chicago.

Pharmasyntez portfolio includes more than 30 drugs for treatment of TB infection

Pharmasyntez, a Russian company, views the manufacturing of TB drugs as a key area of its activities. Today, the products of Pharmasyntez hold 50% of the Russian market for TB drugs.

Generium plans to launch manufacturing of Russian-made Tigratest® in 2019

Anna Kuznetsova, the Children's Rights Commissioner for the President of the Russian Federation, visited GENERIUM, a pharmaceutical company. The purpose of the trip was to visit a shop for manufacturi...

GENERIUM signs agreement to supply biotech drugs to Iran

A trilateral agreement between GENERIUM, the leader of Russian biotechnology, BIOSUN PHARMED, an Iranian company, and RSC Pharm, a Russian company, was signed in the Iranian Embassy in Moscow.

Russian vaccine against TB is ready for Phase II trials

The funds have been already allocated to continue this work over the next two years. The program is financed from the state budget and provides for the allocation of about 60 million rubles in 2018 and about 30 million in 2019.

IIDF invests 195 million rubles in technologies for the treatment of tuberculosis

The Internet Initiatives Development Fund (IIDF) will invest 195 million rubles in Personal Medication & Health Management company. The project is at the intersection of hardware, Internet of Thin...

44 million rubles were invested to develop a TB drug in Russia

drug development
Primer Capital, a venture capital biotech fund, made investments in a drug for the treatment of multi-drug-resistant tuberculosis, developed by MT Medicals.